Bioray Biotech CoROCO:7561 -0.27%82 Pretax Margin % is 15.59% as of Dec. 2025, which is 2193% above its 10-year median of 0.68. GuruFocus rates ROCO:7561 with a GF Score™ of 82/100 and a GF Value™ of NT$29.49 (Significantly Undervalued). Among 956 Drug Manufacturers companies, Bioray Biotech Co ranks better than 78.45% on this metric.
The historical rank and industry rank for Bioray Biotech Co's Pretax Margin % or its related term are showing as below:
ROCO:7561'
s Pretax Margin % Range Over the Past 10 Years
Min: -7.4 Med: 0.68 Max: 18.52
Current: 18.52
ROCO:7561's Pretax Margin % is ranked better than 78.45% of 956
companies
in the Drug Manufacturers industry
Industry Median: 7.285
vs ROCO:7561: 18.52
Bioray Biotech Co (ROCO:7561) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Bioray Biotech Co Pretax Margin % Related Terms
Bioray Biotech Co Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Bioray Biotech Co's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7561 vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bioray Biotech Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioray Biotech Co Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bioray Biotech Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Bioray Biotech Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioray Biotech Co (ROCO:7561) has a Pretax Margin % of 15.59% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Bioray Biotech Co and its competitors. This is 2193% above median its historical median of 0.68. According to the industry distribution chart, Bioray Biotech Co ranks #206 out of 956 companies in the Drug Manufacturers industry, placing it in the top 21.5%.
Is Bioray Biotech Co's Pretax Margin % too high?
Bioray Biotech Co's current Pretax Margin % of 15.59% is 2193% above median its 10-year median of 0.68. The Drug Manufacturers industry median Pretax Margin % is 7.29. Bioray Biotech Co's value of 15.59% is 114% above this industry median. Based on the distribution chart, Bioray Biotech Co ranks #206 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bioray Biotech Co has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioray Biotech Co's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bioray Biotech Co ranks #206 out of 956 companies for Pretax Margin %. This places Bioray Biotech Co in the top 22% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.29. Bioray Biotech Co's value of 15.59% is 114% above this benchmark. While the company's 10-year median is 0.68 vs. the industry median of 7.29, Bioray Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.29, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioray Biotech Co's current Pretax Margin % of 15.59% is 114% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Bioray Biotech Co and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioray Biotech Co's current Pretax Margin % is 15.59%, which is 2193% above median its own 10-year median of 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioray Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Bioray Biotech Co (ROCO:7561) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$29.49, compared to a current price of NT$18.80 — trading 36.2% below its estimated fair value. The current Pretax Margin % is 15.59%, which is 2193% above median its 10-year median of 0.68 and 114% above the Drug Manufacturers industry median of 7.29. Bioray Biotech Co's overall GF Score™ is 82/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Bioray Biotech Co (ROCO:7561), the current Pretax Margin % is 15.59% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioray Biotech Co (ROCO:7561) Overvalued in 2026?
Based on GuruFocus' analysis, Bioray Biotech Co stock appears to be undervalued.
The current stock price of NT$18.80 is trading 36.2% below its estimated GF Value™ of NT$29.49.
GuruFocus considers Bioray Biotech Co to be Significantly Undervalued.
Key valuation signals for ROCO:7561:
Pretax Margin %: 15.59% (2193% above median its 10-year median of 0.68)
GF Value™: NT$29.49 vs. price of NT$18.80 (36.2% below fair value)
Industry Position: 114% above the Drug Manufacturers median (#206 of 956)
No single metric tells the full story. See the ROCO:7561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioray Biotech Co Ltd is engaged in the development and manufacturing of biological agents, including functional probiotics, medicinal fungi, and immune cell preparations.
82GF Score
Get the complete analysis for ROCO:7561
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7561 has been successfully added to your 
